Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Exact Sciences Corporation - Common Stock (NQ:EXAS)

52.94 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 16, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Exact Sciences Corporation - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Demystifying Exact Sciences: Insights From 9 Analyst Reviews
 
Via Benzinga
Exact Sciences Launches Cancerguard™, First-of-Its-Kind Multi-Cancer Early Detection Blood Test
From Exact Sciences Corp.
Via Business Wire
Wayfair, United Therapeutics, And Ciena Are Among The Top 10 Large-Cap Gainers Last Week (July 14-July 18): Are The Others In Your Portfolio?
These ten large-cap stocks were top performers last week. Are they a part of your portfolio? 
Via Benzinga
Why Exact Sciences (EXAS) Stock Is Trading Up Today
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 6.3% in the afternoon session after extending its positive momentum as RBC Capital Markets raised its price target on the... 
Via StockStory
Why IBD 50's Guardant Health Just Tumbled, Breaking A 67% Monthlong Run
The company is working on a second version of its colon cancer screening test, Shield. 
Via Investor's Business Daily
Immuno-Oncology Q2 Earnings: Regeneron (NASDAQ:REGN) Simply the Best
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Regeneron (NASDAQ:REGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
Exact Sciences (EXAS) Stock Trades Up, Here Is Why
Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) jumped 1.5% in the afternoon session after RBC Capital Markets raised its price target on the company. The investment bank... 
Via StockStory
Topics Artificial Intelligence Economy
3 of Wall Street’s Favorite Stocks We’re Skeptical Of
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because... 
Via StockStory
Exact Sciences to Participate in September Investor Conferences
From Exact Sciences Corp.
Via Business Wire
3 Unprofitable Stocks We Think Twice About
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, these businesses risk running out of capital... 
Via StockStory
Sotera Health Company, Incyte, Exact Sciences, Bausch + Lomb, and Addus HomeCare Shares Skyrocket, What You Need To Know
A number of stocks jumped in the afternoon session after markets continued to rally amid growing speculation of an impending interest rate cut by the Federal Reserve. Following a favorable Consumer... 
Via StockStory
Topics Economy Lawsuit
1 Small-Cap Stock to Own for Decades and 2 We Turn Down
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
Micron To Rally More Than 49%? Here Are 10 Top Analyst Forecasts For Tuesday
 
Via Benzinga
EXAS Q2 Deep Dive: Portfolio Expansion and Productivity Drive Guidance Increase Amid Market Caution
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) announced better-than-expected revenue in Q2 CY2025, with sales up 16% year on year to $811.1 million. The company’s full-year revenue... 
Via StockStory
3 Out-of-Favor Stocks We Steer Clear Of
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds. 
Via StockStory
Topics Supply Chain
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
The rock-star money manager is making the most of sell-offs in some of her stocks. 
Via The Motley Fool
Beyond The Numbers: 7 Analysts Discuss Exact Sciences Stock
 
Via Benzinga
Top 3 Health Care Stocks That Are Preparing To Pump This Month
 
Via Benzinga
Exact Sciences Dip A Chance To Buy As Freenome Deal Fortifies Future: Analyst
Exact Sciences beat Q2 expectations, raised its 2025 forecast, and secured U.S. rights to Freenome's CRC blood tests in a major strategic move. 
Via Benzinga
Discover the top movers in Thursday's pre-market session.
The US market is yet to commence its session on Thursday, but let's get a preview of the pre-market session and explore the top gainers and losers driving the early market movements. 
Via Chartmill
Redwire Posts Downbeat Q2 Results, Joins Tandem Diabetes Care, Fortinet, Symbotic And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Via Benzinga
Why Groupon Shares Are Trading Higher By Around 28%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Exact Sciences (NASDAQ:EXAS) Reports Strong Q2 But Stock Drops 15.2%
Diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) reported Q2 CY2025 results exceeding the market’s revenue expectations, with sales up 16% year on year to $811.1 million. The company’s... 
Via StockStory
Exact Sciences (EXAS) Q2 Revenue Up 16%
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's After-Market Session
 
Via Benzinga
Stay updated with the stocks that are on the move in today's after-hours session.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session. 
Via Chartmill
How Exact Sciences Is Spending $775 Million To Dominate The Cancer-Screening Market
The company is expanding its oncology efforts with a deal for a blood-based colorectal cancer screening test. 
Via Investor's Business Daily
Topics Earnings
Exact Sciences Announces Second Quarter 2025 Results
From Exact Sciences Corp.
Via Business Wire
Exact Sciences Announces Exclusive License with Freenome for Blood-Based Colorectal Cancer Screening Tests
From Exact Sciences Corp.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.